GlassScriptPhysician profile
Piyush Bhatnagar
NPI 1811961907
$9,102.11
in general payments reported to CMS, 2019-2025
52 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $536 · 2021: $1,329 · 2022: $1,734 · 2023: $1,106 · 2024: $1,518 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,248 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122 · Education: $28.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,247.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122.00 |
| Education | $28.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $710.27 | 2019-2025 | Spravato |
| Abbvie INC. | $648.60 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $601.36 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $593.02 | 2022-2024 | Nuplazid |
| Astellas Pharma US INC | $571.03 | 2019-2025 | Veozah |
| Amgen INC. | $450.58 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $397.08 | 2019-2025 | |
| Lilly USA, LLC | $391.22 | 2019-2024 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $384.73 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $350.59 | 2020-2025 | Airsupra, Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $336.17 | 2019-2025 | |
| Novo Nordisk INC | $270.32 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Jazz Pharmaceuticals INC. | $253.59 | 2022-2023 | Epidiolex |
| Axsome Therapeutics, INC. | $245.62 | 2023-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $240.16 | 2023-2024 | Gemtesa, Aptiom |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Piyush Bhatnagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.